Kezar Life Sciences Inc
NASDAQ:KZR
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.6942
  • TODAY'S CHANGE (%)
    -0.0157 (-2.2116%)
  • Bid / Lots
    0.6888/ 5
  • Ask / Lots
    0.7000/ 4
  • Open / Previous Close
    0.7133 / 0.7099
  • Day Range
    0.6832
    0.7184
  • 52 Week Range
    0.6452
    2.7400
  • Volume
    214,288

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Jun 7, 2024

      Show headlines and story abstract

    • 5:59PM ET on Friday Jun 07, 2024 by Business Wire
      Companies Mentioned: KZR

      Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company's Board of Directors granted one employee a nonqualified stock option to purchase 80,000 shares of its common stock with an exercise price of $0.71 per share, which is equal to the closing price of Kezar's common stock on June 3, 2024, the grant date of the award. The stock option was granted as an inducement award material to the individual entering into employment with Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4).

    • 5:59PM ET on Friday Jun 07, 2024 by Dow Jones
      Companies Mentioned: KZR
      SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--June 07, 2024--
      Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company's Board of Directors granted one employee a nonqualified stock option to purchase 80,000 shares of its common stock with an exercise price of $0.71 per share, which is equal to the closing price of Kezar's common stock on June 3, 2024, the grant date of the award. The stock option was granted as an inducement award material to the individual entering into employment with Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4).

  • May 29, 2024

Peers Headlines